- Home
- CVLT vs JAZZ Comparison
CVLT vs JAZZ Comparison
Compare CVLT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVLT
- JAZZ
- Stock Information
- Founded
- CVLT 1996
- JAZZ 2003
- Country
- CVLT United States
- JAZZ Ireland
- Employees
- CVLT N/A
- JAZZ N/A
- Industry
- CVLT Computer Software: Prepackaged Software
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CVLT Technology
- JAZZ Health Care
- Exchange
- CVLT Nasdaq
- JAZZ Nasdaq
- Market Cap
- CVLT 6.8B
- JAZZ 7.3B
- IPO Year
- CVLT 2006
- JAZZ 2007
- Fundamental
- Price
- CVLT $183.15
- JAZZ $108.07
- Analyst Decision
- CVLT Buy
- JAZZ Strong Buy
- Analyst Count
- CVLT 10
- JAZZ 13
- Target Price
- CVLT $182.75
- JAZZ $181.85
- AVG Volume (30 Days)
- CVLT 432.0K
- JAZZ 1.3M
- Earning Date
- CVLT 04-29-2025
- JAZZ 05-06-2025
- Dividend Yield
- CVLT N/A
- JAZZ N/A
- EPS Growth
- CVLT N/A
- JAZZ 49.21
- EPS
- CVLT 1.68
- JAZZ 7.51
- Revenue
- CVLT $995,619,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- CVLT $15.91
- JAZZ $5.92
- Revenue Next Year
- CVLT $11.79
- JAZZ $4.22
- P/E Ratio
- CVLT $109.02
- JAZZ $14.39
- Revenue Growth
- CVLT 18.63
- JAZZ 5.76
- 52 Week Low
- CVLT $105.76
- JAZZ $95.49
- 52 Week High
- CVLT $190.11
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CVLT 62.67
- JAZZ 47.97
- Support Level
- CVLT $170.00
- JAZZ $106.69
- Resistance Level
- CVLT $178.76
- JAZZ $110.48
- Average True Range (ATR)
- CVLT 5.12
- JAZZ 3.56
- MACD
- CVLT -0.29
- JAZZ 0.55
- Stochastic Oscillator
- CVLT 91.45
- JAZZ 68.77
About CVLT Commvault Systems Inc.
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Commvault Complete Backup and Recovery, HyperScale, Hedvig, and Metallic. The company operates in the United States and exports to many other countries.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.